Advent, a leading global private equity investor, announces that funds managed by Advent have signed a definitive agreement to invest USD $175 million via primary and secondary for a significant minority stake in Dublin headquartered Felix Pharmaceuticals Pvt Ltd (“Felix”), a leading global Gx animal pharma player. Felix Pharma is one of the fastest growing developers and manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded Gx players for private labelling, particularly in the US. With a portfolio of 14 approved products from USFDA and many more under review and development, Felix has the widest portfolio of products in the industry.
Read the full article: Advent to Acquire a Significant Minority Stake in Felix Pharmaceuticals, Ireland //
Source: https://www.adventinternational.com/news/advent-to-acquire-a-significant-minority-stake-in-felix-pharmaceuticals-ireland/